{"id":"labr-312","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL3652459","moleculeType":"Small molecule","molecularWeight":"407.45"},"_dailymed":null,"mechanism":{"_ai_source":"featherless-qwen","explanation":"As an investigational compound, the precise biological pathways and targets affected by LABR-312 are being studied in clinical trials to determine its therapeutic effects.","oneSentence":"LABR-312's mechanism of action is currently under investigation and not fully characterized.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T04:03:02.543Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT02645799","phase":"PHASE2","title":"BLADE-PCI Trial (BLADE); PHASE IIB LIPOSOMAL ALENDRONATE STUDY","status":"UNKNOWN","sponsor":"BIOrest Ltd.","startDate":"2016-04","conditions":"Diabetes Mellitus","enrollment":270}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"LABR-312","genericName":"LABR-312","companyName":"BIOrest Ltd.","companyId":"biorest-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}